Nebraska will receive nearly $5 million from Abbott Laboratories to settle concerns that it improperly marketed its anti-seizure drug Depakote.
Nebraska Attorney General Jon Bruning says the state will receive a share of the $1.5 billion settlement Abbott agreed to.
Nebraska's Medicaid program will receive $3.7 million, and $1.2 million will go to the state's consumer settlement fund.
Depakote is an anti-seizure and mood-stabilizing drug that's prescribed for bipolar disorder. Abbott admitted marketing Depakote for unapproved uses including dementia and schizophrenia in violation of FDA rules.
The national settlement was announced Monday.